MaaT Pharma

As of December 31, 2025, MaaT Pharma carries a market capitalization of 70.39M, placing it among publicly traded companies globally. Its enterprise value stands at 60.83M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

MaaT Pharma's next confirmed earnings release is scheduled for April 1, 2027.

As of December 31, 2025, MaaT Pharma has 18.82M shares outstanding.

These figures are as of December 31, 2025.

As of December 31, 2025, MaaT Pharma maintains a current ratio of 1.94, meaning it holds 1.9x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended December 31, 2025.

As of the close on October 22, 2026, MaaT Pharma's stock has declined approximately 74.64% over the past 52 weeks. The 50-day moving average sits at 1.94, while the 200-day moving average is 4.21.

As of December 31, 2025, MaaT Pharma holds 24.96M in cash and equivalents against 15.40M in total debt, resulting in a net debt position of -14.49M. Total book value stands at 1.80M, with working capital of 16.02M providing operational flexibility.